Last reviewed · How we verify
CG400549
CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses.
CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses. Used for Multiple myeloma, Peripheral T-cell lymphoma.
At a glance
| Generic name | CG400549 |
|---|---|
| Also known as | Cohort 3 |
| Sponsor | CrystalGenomics, Inc. |
| Drug class | HDAC6 inhibitor |
| Target | HDAC6 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Neurology |
| Phase | Phase 2 |
Mechanism of action
HDAC6 inhibition leads to accumulation of acetylated alpha-tubulin and aggresome formation, which enhances the clearance of protein aggregates implicated in neurodegenerative diseases. Additionally, HDAC6 inhibition can modulate T-cell function and enhance anti-tumor immunity, making it relevant for both neurological and oncological indications.
Approved indications
- Multiple myeloma
- Peripheral T-cell lymphoma
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Thrombocytopenia
Key clinical trials
- Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus (PHASE2)
- CG400549 Single Ascending Dose Study (PHASE1)
- Multiple Ascending Doses Study of CG400549 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |